Skip to main content
S 303 104th Congress Senate

Biomaterials Access Assurance Act of 1995

Official title: A bill to establish rules governing product liability actions against raw materials and bulk component suppliers to medical device manufacturers, and for other purposes.

Introduced: February 22, 1995 See on congress.gov
Commerce Administrative procedureArtificial implantsBiomedical engineeringBiomedical materials
More subjectsShow fewer subjects
Civil procedureDepartment of Health and Human ServicesDiscovery (Law)Evidence (Law)Federal preemptionFrivolous lawsuitsGovernment Operations and PoliticsHealthLawLegal feesManufacturing industriesMaterialsMedical suppliesProducts liabilityRaw materials
This bill died when the 104th Congress ended
It never became law before the 104th Congress (1995–1996) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 31, 1995
Read twice and referred to the Committee on Commerce.
Jan 31, 1995
Sponsor introductory remarks on measure. (CR S1853-1854)
Jan 31, 1995
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action January 31, 1995

Read twice and referred to the Committee on Commerce.

 Plain-English summary Congressional Research Service

Biomaterials Access Assurance Act of 1995 - Provides that, in any civil action, a biomaterials supplier (one who supplies components or raw materials used to manufacture implants) may raise any defense provided under this Act.

Exempts a biomaterials supplier (supplier) from liability for harm to a claimant caused by an implant, with exceptions in the case of a supplier who: (1) is a registered manufacturer of the implant; (2) is a seller of the implant and who held title to the implant at the time of sale; or (3) furnishes raw materials or components that fail to meet applicable contractual requirements or specifications. Provides grounds for liability with respect to each exception. Outlines procedural guidelines for the dismissal of civil actions against suppliers, including the submission of appropriate affidavits in support of, or in defense to, a claim. States that a supplier may be considered a manufacturer of an implant, for purposes of such civil actions, only if the supplier has registered with the Secretary of Health and Human Services and included the implant on a list of devices filed pursuant to the Federal Food, Drug, and Cosmetic Act. Requires claimant payment of attorney's fees if the court finds the claim to be without merit and frivolous.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 303: Biomaterials Access Assurance Act of 1995. 104th Congress. Open America. https://openamerica.io/bill/104-S-303/
MLA
"S. 303: Biomaterials Access Assurance Act of 1995." 104th Congress, 2026, Open America, https://openamerica.io/bill/104-S-303/.
Bluebook (legal)
S. 303, 104th Cong. (2026), https://openamerica.io/bill/104-S-303/.
Markdown link
[S. 303: Biomaterials Access Assurance Act of 1995](https://openamerica.io/bill/104-S-303/)
Report a problem